Ownership and Interoperability Challenges of Alzheimer Monoclonal Antibody Registries-Reference-Cited by-同舟云学术

Ownership and Interoperability Challenges of Alzheimer Monoclonal Antibody Registries

Published:2023-12-11 Issue: Volume: Page:
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Socal Mariana P.¹,Odouard Ilina C.¹,Kharrazi Hadi¹²

Affiliation:

1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

2. Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland

Abstract

This Viewpoint addresses the challenges that the Centers for Medicare and Medicaid Services faces to collect real-world data on the effectiveness and safety of lecanemab from external registries to achieve its coverage with evidence development objectives.

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2812781/jamaneurology_socal_2023_vp_230017_1701788696.18538.pdf

Reference7 articles.

1. The Surveillance, Epidemiology, and End Results (SEER) program and pathology: toward strengthening the critical relationship.;Duggan;Am J Surg Pathol,2016

2. Assessment of outcomes associated with the use of newly approved oncology drugs in Medicare beneficiaries.;Green;JAMA Netw Open,2021

3. A framework and standardized methodology for developing minimum clinical datasets.;Svensson-Ranallo;AMIA Jt Summits Transl Sci Proc,2011

4. Blueprint for harmonizing unstandardized disease registries to allow federated data analysis: prepare for the future.;Kroes;ERJ Open Res,2022

5. Assessing the impact of privacy-preserving record linkage on record overlap and patient demographic and clinical characteristics in PCORnet, the National Patient-Centered Clinical Research Network.;Marsolo;J Am Med Inform Assoc,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Talking With Patients About the New Anti-amyloid Alzheimer Disease Medications;Annals of Internal Medicine;2024-02